<p>史蒂夫·科恩管理着 <strong>Point72 资产管理公司</strong>，投资者密切关注他通过该对冲基金的 13F 文件所做的投资决策。最近的 13F 文件突出了两个有趣的举动。首先，科恩在人工智能领军企业 <strong>亚马逊</strong>（AMZN 0.80%）和 <strong>英伟达</strong>（NVDA +3.74%）上获利了结。其次，他大幅增加了在 <strong>波士顿科学</strong>（BSX 1.08%）的持仓。</p>
<p>以下是史蒂夫·科恩的股票买卖情况，以及你可能想考虑进行类似投资的原因。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84NzcwMzIvMjNfMTFfMDYtYS1wZXJzb24tbG9va2luZy1hdC1hLXN0b2NrLXRyYWRpbmctcGhvbmUtYXBwLV9tZi1kbG9hZC1nZXR0eWltYWdlcy0xNDM2NzQzNDk3LmpwZyZ3PTM4NDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="3840" height="2560" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84NzcwMzIvMjNfMTFfMDYtYS1wZXJzb24tbG9va2luZy1hdC1hLXN0b2NrLXRyYWRpbmctcGhvbmUtYXBwLV9tZi1kbG9hZC1nZXR0eWltYWdlcy0xNDM2NzQzNDk3LmpwZyZ3PTM4NDA"/></p>
<p>图片来源：Getty Images。</p>
<h2>人工智能交易可能正在改变</h2>
<p>自 2026 年初以来，亚马逊和英伟达的表现并不特别强劲。截至目前，亚马逊和英伟达的年初至今涨幅仅约 5%，落后于 <strong>标准普尔 500 指数</strong>（^GSPC 0.28%）约 10% 的涨幅。这是在这两家公司经历了多年的上涨之后。</p>
<p>在过去十年中，亚马逊上涨超过 560%，而标准普尔 500 指数上涨 260%。英伟达的股票在同一时期上涨超过 16000%。从表现强劲的股票中获利了结并不令人惊讶，尤其是在它们在经历了长时间的强势后开始落后于大盘时。</p>
<p>然而，值得注意的是，推动这两只股票上涨的 人工智能交易 似乎正在发生变化。早期的领军者可能正在让位于基础设施公司，例如氢燃料电池制造商 <strong>Bloom Energy</strong>（BE 5.76%），这些公司支持人工智能基础设施的建设。在 2025 年第四季度到 2026 年第一季度之间，科恩将其在亚马逊的持股削减了 6%，在英伟达的持股则大幅减少了 24%。</p>
<p></p>
<p>NVDA 数据由 YCharts 提供</p>
<h2>科恩押注于一个被冷落的医疗巨头</h2>
<p>在科恩出售英伟达和亚马逊股票的同时，他在购买波士顿科学的股票。他在这家 医疗设备制造商 的持仓从年初增加了 50%。有趣的是，由于该股票大幅下跌，波士顿科学的持仓美元价值几乎没有变化。截至目前，该股票年初至今下跌超过 50%。这是一个价值投资，科恩可能押注于该公司在长期内扭转局面。</p>
<p>波士顿科学制造用于心脏护理的医疗设备（占收入的 66%）和医疗外科产品（占 34%）。它销售的产品并非可选，因此无论经济趋势和市场周期如何，需求都保持稳定。该公司长期以来一直是医疗技术领域的顶尖企业。然而，所有公司都会经历好的时期和坏的时期。目前，波士顿科学的表现并不理想。</p>
<p>值得注意的是，该公司报告了强劲的第一季度业绩，但对全年提供了特别疲软的前景。这里的数字说明了一切。在 2026 年第一季度，波士顿科学的有机销售增长为 9.4%，但在第二季度，它预计有机销售增长可能会放缓至低至 5%。对于整个年度，该公司将调整后的每股收益指引范围从 3.43 美元至 3.49 美元下调至 3.34 美元至 3.41 美元。</p>
<p>展开</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vYXJ0L2NvbXBhbnlsb2dvcy9tYXJrL0JTWC5wbmcmdz0xMjg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="波士顿科学股票报价" width="80" height="80" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vYXJ0L2NvbXBhbnlsb2dvcy9tYXJrL0JTWC5wbmcmdz0xMjg"/></p>
<h2>NYSE: BSX</h2>
<p>波士顿科学</p>
<p>今日变动</p>
<p>(-1.08%) $-0.49</p>
<p>当前价格</p>
<p>$44.81</p>
<h3>关键数据点</h3>
<p>市值</p>
<p>$67B 市值仅计算公开交易的流通股。不包括未上市、私有或双重类别的非交易股份。隐含市值可能会有所不同。市值仅计算公开交易的流通股。不包括未上市、私有或双重类别的非交易股份。隐含市值可能会有所不同。</p>
<p>日内区间</p>
<p>$44.01 - $44.98</p>
<p>52 周区间</p>
<p>$42.25 - $109.50</p>
<p>成交量</p>
<p>1350 万</p>
<p>平均成交量</p>
<p>2060 万</p>
<p>毛利率</p>
<p>65.44%</p>
<p>投资者目前情绪低迷的原因在于：指引范围的新高端低于旧低端。但该公司有着悠久的成功历史，得益于创新和强大的客户关系。它是少数几家在行业中占据稳固地位的医疗设备制造商之一。该公司最终很可能会走出当前的低迷。</p>
<h2>波士顿科学：一个深度价值机会</h2>
<p>然而，目前投资者关注的主要故事是波士顿科学的估值。例如，其市销率为 3.2 倍，远低于其五年平均的 6 倍。而其市盈率为 19 倍，远低于其长期平均的 64 倍。公平地说，购买像波士顿科学这样的价值导向股票应被视为长期投资。</p>
<p>确实，你无法在一夜之间扭转一家市值超过 600 亿美元的医疗巨头。但这家行业领先的医疗设备制造商最终似乎很可能会恢复正轨。这也可能是史蒂夫·科恩所押注的，你也可能想要这样做。</p>

英伟达

波士顿科学

亚马逊

<p>亿万富翁史蒂夫·科恩的 Point72 资产管理公司最近出售了在人工智能领军企业亚马逊和英伟达的持仓，因其近期相对于大盘表现不佳而获利了结。同时，他将在波士顿科学的持股比例大幅提高了 50%，认为这家受挫的医疗设备制造商是一个深度价值机会。尽管波士顿科学最近的股价下跌且下调了盈利指引，科恩似乎仍在押注其长期反弹潜力，考虑到其强大的市场地位和吸引人的估值指标</p>

<p>Steve Cohen runs <strong>Point72 Asset Management</strong>, and investors closely watch his investment decisions through that hedge fund's 13F filings. The most recent 13F highlighted two interesting moves. First, Cohen took profits in artificial intelligence leaders <strong>Amazon</strong>( AMZN 0.80%) and <strong>Nvidia</strong>( NVDA +3.74%). Second, he dramatically increased his position in <strong>Boston Scientific</strong>( BSX 1.08%).</p>
<div class="lb-trans"><p>史蒂夫·科恩管理着 <strong>Point72 资产管理公司</strong>，投资者密切关注他通过该对冲基金的 13F 文件所做的投资决策。最近的 13F 文件突出了两个有趣的举动。首先，科恩在人工智能领军企业 <strong>亚马逊</strong>（AMZN 0.80%）和 <strong>英伟达</strong>（NVDA +3.74%）上获利了结。其次，他大幅增加了在 <strong>波士顿科学</strong>（BSX 1.08%）的持仓。</p>
</div><p>Here's a look at Steve Cohen's stock buying and selling and why you might want to consider making similar investment moves.</p>
<div class="lb-trans"><p>以下是史蒂夫·科恩的股票买卖情况，以及你可能想考虑进行类似投资的原因。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84NzcwMzIvMjNfMTFfMDYtYS1wZXJzb24tbG9va2luZy1hdC1hLXN0b2NrLXRyYWRpbmctcGhvbmUtYXBwLV9tZi1kbG9hZC1nZXR0eWltYWdlcy0xNDM2NzQzNDk3LmpwZyZ3PTM4NDA" alt="A person looking at a stock trading phone app." original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F877032%2F23_11_06-a-person-looking-at-a-stock-trading-phone-app-_mf-dload-gettyimages-1436743497.jpg&amp;w=3840&amp;op=resize"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>The AI trade could be changing</h2>
<div class="lb-trans"><h2>人工智能交易可能正在改变</h2>
</div><p>Since the start of 2026, neither Amazon nor Nvidia have been a particularly strong performer. Amazon and Nvidia were only up around 5% year to date as of this writing, trailing the roughly 10% gain of the <strong>S&amp;P 500 index</strong>( ^GSPC 0.28%). That comes after a multi-year advance for each company.</p>
<div class="lb-trans"><p>自 2026 年初以来，亚马逊和英伟达的表现并不特别强劲。截至目前，亚马逊和英伟达的年初至今涨幅仅约 5%，落后于 <strong>标准普尔 500 指数</strong>（^GSPC 0.28%）约 10% 的涨幅。这是在这两家公司经历了多年的上涨之后。</p>
</div><p>Over the past decade, Amazon was up over 560% compared to a gain of 260% for the S&amp;P 500 index. Nvidia's stock rose more than 16,000% over the same span. Taking profits from strongly performing stocks is hardly shocking, especially as they start to lag the broader market after a long period of strength.</p>
<div class="lb-trans"><p>在过去十年中，亚马逊上涨超过 560%，而标准普尔 500 指数上涨 260%。英伟达的股票在同一时期上涨超过 16000%。从表现强劲的股票中获利了结并不令人惊讶，尤其是在它们在经历了长时间的强势后开始落后于大盘时。</p>
</div><p>However, what's notable is that the artificial intelligence trade that helped push these two stocks higher appears to be shifting. The early leaders may be giving way to infrastructure companies, such as hydrogen fuel cell maker <strong>Bloom Energy</strong>( BE 5.76%), that support the build-out of the AI backbone. Between the fourth quarter of 2025 and the first quarter of 2026, Cohen trimmed his stake in Amazon by 6% and his Nvidia position by a whopping 24%.</p>
<div class="lb-trans"><p>然而，值得注意的是，推动这两只股票上涨的 人工智能交易 似乎正在发生变化。早期的领军者可能正在让位于基础设施公司，例如氢燃料电池制造商 <strong>Bloom Energy</strong>（BE 5.76%），这些公司支持人工智能基础设施的建设。在 2025 年第四季度到 2026 年第一季度之间，科恩将其在亚马逊的持股削减了 6%，在英伟达的持股则大幅减少了 24%。</p>
</div><p></p>
<div class="lb-trans"><p></p>
</div><p>NVDA data by YCharts</p>
<div class="lb-trans"><p>NVDA 数据由 YCharts 提供</p>
</div><h2>Cohen is betting on an unloved healthcare giant</h2>
<div class="lb-trans"><h2>科恩押注于一个被冷落的医疗巨头</h2>
</div><p>While Cohen was selling Nvidia and Amazon shares, he was buying Boston Scientific shares. His position in this medical device maker increased by 50% from the start of the year. What's interesting is that the dollar value of the Boston Scientific position barely budged because the stock has been heading sharply lower. It is down over 50% year to date as of this writing. This is a value play, with Cohen likely betting that the company turns its fortunes around over the long term.</p>
<div class="lb-trans"><p>在科恩出售英伟达和亚马逊股票的同时，他在购买波士顿科学的股票。他在这家 医疗设备制造商 的持仓从年初增加了 50%。有趣的是，由于该股票大幅下跌，波士顿科学的持仓美元价值几乎没有变化。截至目前，该股票年初至今下跌超过 50%。这是一个价值投资，科恩可能押注于该公司在长期内扭转局面。</p>
</div><p>Boston Scientific makes medical devices used in cardiac care (66% of revenues) and medical-surgical products (34%). The products it sells are not optional, so demand is steady regardless of economic trends and market cycles. The company has long been a top player in the medical technology space. However, all companies go through good periods and bad ones. Right now, Boston Scientific isn't hitting on all cylinders.</p>
<div class="lb-trans"><p>波士顿科学制造用于心脏护理的医疗设备（占收入的 66%）和医疗外科产品（占 34%）。它销售的产品并非可选，因此无论经济趋势和市场周期如何，需求都保持稳定。该公司长期以来一直是医疗技术领域的顶尖企业。然而，所有公司都会经历好的时期和坏的时期。目前，波士顿科学的表现并不理想。</p>
</div><p>Notably, the company reported a strong first quarter, but provided a particularly weak outlook for the rest of the year. The numbers here speak volumes. In the first quarter of 2026, Boston Scientific posted organic sales growth of 9.4%, but in the second quarter, it projects organic sales growth could slow to as low as 5%. For the full year, the company lowered its adjusted earnings guidance range from $3.43 to $3.49 per share to a range of $3.34 to $3.41.</p>
<div class="lb-trans"><p>值得注意的是，该公司报告了强劲的第一季度业绩，但对全年提供了特别疲软的前景。这里的数字说明了一切。在 2026 年第一季度，波士顿科学的有机销售增长为 9.4%，但在第二季度，它预计有机销售增长可能会放缓至低至 5%。对于整个年度，该公司将调整后的每股收益指引范围从 3.43 美元至 3.49 美元下调至 3.34 美元至 3.41 美元。</p>
</div><p>Expand</p>
<div class="lb-trans"><p>展开</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vYXJ0L2NvbXBhbnlsb2dvcy9tYXJrL0JTWC5wbmcmdz0xMjg" alt="Boston Scientific Stock Quote" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Fart%2Fcompanylogos%2Fmark%2FBSX.png&amp;w=128&amp;op=resize"/></p>
<h2>NYSE: BSX</h2>
<div class="lb-trans"><h2>NYSE: BSX</h2>
</div><p>Boston Scientific</p>
<div class="lb-trans"><p>波士顿科学</p>
</div><p>Today's Change</p>
<div class="lb-trans"><p>今日变动</p>
</div><p>(-1.08%) $-0.49</p>
<div class="lb-trans"><p>(-1.08%) $-0.49</p>
</div><p>Current Price</p>
<div class="lb-trans"><p>当前价格</p>
</div><p>$44.81</p>
<div class="lb-trans"><p>$44.81</p>
</div><h3>Key Data Points</h3>
<div class="lb-trans"><h3>关键数据点</h3>
</div><p>Market Cap</p>
<div class="lb-trans"><p>市值</p>
</div><p>$67BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.</p>
<div class="lb-trans"><p>$67B 市值仅计算公开交易的流通股。不包括未上市、私有或双重类别的非交易股份。隐含市值可能会有所不同。市值仅计算公开交易的流通股。不包括未上市、私有或双重类别的非交易股份。隐含市值可能会有所不同。</p>
</div><p>Day's Range</p>
<div class="lb-trans"><p>日内区间</p>
</div><p>$44.01 - $44.98</p>
<div class="lb-trans"><p>$44.01 - $44.98</p>
</div><p>52wk Range</p>
<div class="lb-trans"><p>52 周区间</p>
</div><p>$42.25 - $109.50</p>
<div class="lb-trans"><p>$42.25 - $109.50</p>
</div><p>Volume</p>
<div class="lb-trans"><p>成交量</p>
</div><p>13.5M</p>
<div class="lb-trans"><p>1350 万</p>
</div><p>Avg Vol</p>
<div class="lb-trans"><p>平均成交量</p>
</div><p>20.6M</p>
<div class="lb-trans"><p>2060 万</p>
</div><p>Gross Margin</p>
<div class="lb-trans"><p>毛利率</p>
</div><p>65.44%</p>
<div class="lb-trans"><p>65.44%</p>
</div><p>There's a reason investors are downbeat right now: the new high end of the guidance range is lower than the old low end. But the company has a long history of success, driven by innovation and strong customer relationships. It is one of a small number of medical device makers that have entrenched industry positions. It is highly likely that the company will eventually emerge from its current funk.</p>
<div class="lb-trans"><p>投资者目前情绪低迷的原因在于：指引范围的新高端低于旧低端。但该公司有着悠久的成功历史，得益于创新和强大的客户关系。它是少数几家在行业中占据稳固地位的医疗设备制造商之一。该公司最终很可能会走出当前的低迷。</p>
</div><h2>Boston Scientific: A deep value opportunity</h2>
<div class="lb-trans"><h2>波士顿科学：一个深度价值机会</h2>
</div><p>The big story for investors right now, however, is Boston Scientific's valuation. For example, its price-to-sales ratio of 3.2x is far below its five-year average of 6x. And its price-to-earnings ratio of 19x is well below its longer-term average of 64x. To be fair, buying a value-oriented stock like Boston Scientific should be viewed as a long-term investment.</p>
<div class="lb-trans"><p>然而，目前投资者关注的主要故事是波士顿科学的估值。例如，其市销率为 3.2 倍，远低于其五年平均的 6 倍。而其市盈率为 19 倍，远低于其长期平均的 64 倍。公平地说，购买像波士顿科学这样的价值导向股票应被视为长期投资。</p>
</div><p>Indeed, you can't turn an over $60 billion market cap healthcare giant around on a dime. But it seems highly likely that this industry-leading medical device maker does, eventually, get back on track. Which is likely what Steve Cohen is betting on, and you might want to, too.</p>
<div class="lb-trans"><p>确实，你无法在一夜之间扭转一家市值超过 600 亿美元的医疗巨头。但这家行业领先的医疗设备制造商最终似乎很可能会恢复正轨。这也可能是史蒂夫·科恩所押注的，你也可能想要这样做。</p>
</div>

Billionaire Steve Cohen Sold Amazon and Nvidia but Loaded Up on This Beaten-Down Stock

- Steve Cohen 在投资中减持亚马逊和英伟达，增加波士顿科学的持股。  
- 亚马逊和英伟达自 2026 年起表现疲软，市值及收益下滑明显。  
- 波士顿科学的估值低于历史平均，具备长期投资潜力。

Motley Fool

英伟达期权收益策略 ETF - YieldMax

南方两倍做多英伟达

2 倍做空 NVDA ETF - GraniteShares

南方两倍做空英伟达

亚马逊每日 1 倍做空 ETF - Direxion

2 倍做多英伟达 ETF - Direxion

GraniteShares 2x Long AMZN Daily ETF

亚马逊每日 2 倍做多 ETF - Direxion

2 倍做空 NVDA ETF - T-Rex

2 倍做多 NVDA ETF - T-Rex

1 倍做空英伟达 ETF - Direxion

1.5 倍做空英伟达 ETF - Tradr

Roundhill AMZN WeeklyPay ETF

ProShares Ultra NVDA

2 倍做多英伟达 ETF - Leverage Shares

2 倍做多英伟达 ETF - GraniteShares

Leverage Shares 2x Cpd Acclrtd NVDAMnETF

NVDA 周配息 ETF - Roundhill

GraniteShares YieldBOOST NVDA ETF

xETFs NVDA Daily Income ETF

NVDA 期权收益策略 ETF - YieldMax

XI二南英伟-U

2 倍做多 MAG7 指数 ETF - Roundhill

Tradr 2X Short AMZN Daily ETF

Yieldmax Amzn Option Income ETF

Graniteshares YieldBOOST AMZN ETF

Kurv Yield Premium Strategy Amazon AMZN ETF

标普 500 指数

Bloom Energy

NVIDIA Corporation

亿万富翁史蒂夫·科恩卖出了亚马逊和英伟达，但增持了这只被低估的股票